Literature DB >> 9386669

Predicting the outcome of postasphyxial hypoxic-ischemic encephalopathy within 4 hours of birth.

P Ekert1, M Perlman, M Steinlin, Y Hao.   

Abstract

OBJECTIVE: To build models that predict severe adverse outcome within 4 hours of birth in patients with postasphyxial hypoxic-ischemic encephalopathy. The goal was to develop models for selecting patients for therapeutic trials of neuroprotective medications. STUDY
DESIGN: Retrospective cohort study with follow-up to a minimum age of 12 months of 164 "outborn" term infants admitted to a tertiary neonatal intensive care unit, and 14 "inborn" term infants in the two tertiary perinatal centers in a regionalized setting. After performing univariate screening tests, multivariate models of association between risk factors and "severe adverse outcome" (death or major neurosensory impairment) were constructed.
RESULTS: Of 178 infants with postasphyxial hypoxic-ischemic encephalopathy of defined severity admitted consecutively between 1985 and 1992, 48 died, 40 survived with major neurosensory impairment, and 13 were lost to follow-up. The important predictors of severe adverse outcome in the first 4 hours were delayed onset of breathing, administration of chest compressions, and seizures. At 60 minutes of age, based on predicted probabilities of > 0.50, the sensitivity of the predictive model was 85% and specificity 68%. The parameter estimates of the predictive models are reported.
CONCLUSIONS: Age of onset of breathing, administration of chest compressions, and age of onset of seizures were the most important variables predictive of adverse outcome in this study. Although fairly sensitive and specific, these predictive models should be applied with caution. To build more accurate models, a template for the conduct of a large, multicenter prospective study is provided.

Entities:  

Mesh:

Year:  1997        PMID: 9386669     DOI: 10.1016/s0022-3476(97)70072-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

1.  Do hyperoxaemia and hypocapnia add to the risk of brain injury after intrapartum asphyxia?

Authors:  G Klinger; J Beyene; P Shah; M Perlman
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-01       Impact factor: 5.747

2.  Amplitude integrated EEG 3 and 6 hours after birth in full term neonates with hypoxic-ischaemic encephalopathy.

Authors:  M C Toet; L Hellström-Westas; F Groenendaal; P Eken; L S de Vries
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-07       Impact factor: 5.747

3.  Efficiency of fractional anisotropy and apparent diffusion coefficient on diffusion tensor imaging in prognosis of neonates with hypoxic-ischemic encephalopathy: a methodologic prospective pilot study.

Authors:  O Brissaud; M Amirault; F Villega; O Periot; J F Chateil; M Allard
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-03       Impact factor: 3.825

4.  Follow-up of the term infant after hypoxic-ischemic encephalopathy.

Authors:  Charlene Mt Robertson; Max Perlman
Journal:  Paediatr Child Health       Date:  2006-05       Impact factor: 2.253

5.  Measurement of the urinary lactate/creatinine ratio for early diagnosis of the hypoxic-ischemic encephalopathy in newborns.

Authors:  Nahid Ghotbi; Babak Najibi
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

6.  Perinatal expression of heat-shock protein 27 in brain regions and nonneural tissues of the piglet.

Authors:  J C David; J Landry; J F Grongnet
Journal:  J Mol Neurosci       Date:  2000-10       Impact factor: 2.866

7.  Effects of xenon gas on human airway epithelial cells during hyperoxia and hypothermia.

Authors:  Y Zhu; J J Mosko; A Chidekel; M R Wolfson; T H Shaffer
Journal:  J Neonatal Perinatal Med       Date:  2020

8.  The TOBY Study. Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy: a randomised controlled trial.

Authors:  Dennis Azzopardi; Peter Brocklehurst; David Edwards; Henry Halliday; Malcolm Levene; Marianne Thoresen; Andrew Whitelaw
Journal:  BMC Pediatr       Date:  2008-04-30       Impact factor: 2.125

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.